Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

References

• Belshe RB, Gruber WC. Prevention ofotitis media in children with live attenuated influenza vaccine given intranasally. Ped. Infect. Dis.j 19, S66–S71 (2000).
   Google Scholar
• Prevention and control of influenza. Morb. Mortal. Weekly Rep. 53,1–40 (2004).
   Google Scholar
• Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl. .1. Med. 338, 11405–11412 (1998).
   Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. .1. Ped. 136,168-175 (2000).
   Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine. J Infect. Dis. 181,1133–1137 (2000).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Mendelman PM, Mallon KP et al, for the Live Attenuated Influenza Virus Vaccine in Healthy Adults Trial Group. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282,137–145 (1999).
   PubMed Web of Science ®Google Scholar
• Gaglani MJ. Piedra PA. Herschler GB et al. Direct and total effectiveness of the intranasal, live attenuated, trivalent cold-adapted influenza virus vaccine against the 2000–2001 influenza A (H 1N1) and B epidemic in healthy children. Arch. Pediatr. Adolesc. Med.158,65-73 (2004).
   Google Scholar
• Halloran ME, Longini IM Jr, Gaglani MJ et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am. J Epiderniol. 158, 305–311 (2003).
   Google Scholar
• Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in preschool aged children. Pediatrics 110,662–672 (2002).
   PubMed Web of Science ®Google Scholar
• Maassab HE Biologic and immunologic characteristics of cold-adapted influenza virus. J II77177111701. 102,728–732 (1969).
   Google Scholar
• Jin H, Lu B, Zhou H et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology306,18–24 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffmann E, Mahmood K, Yang CF et al. Molecular basis for temperature sensitivity and attenuation of the human vaccine strain B/Ann Arbor/1/66. Options for the Control of Influenza V Conference. Okinawa, Japan, Abstract WO7P-51 (2003).
   Google Scholar
• Donabedian AM, DeBorde Dc, Maassab HE Genetics of cold-adapted B/Ann Arbor/1/66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence. Microb. Pathog. 3,97-108 (1987).
   Google Scholar
• Maassab HF, Heilman CA, Herlocher ML. Cold-adapted influenza viruses for use as live vaccines for man. Adv. Biotechnol. Proces. 14,203–242 (1990).
   Google Scholar
• Cox NJ, Maassab HF, Kendal AP. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25° between recent H3N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/10. Virology97,190–194 (1979).
   Google Scholar
• Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of cold-recombinant influenza virus vaccine in ferrets. J Infect. Dis. 146,780–790 (1982).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Keitel WA, Taber LH et al. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978–1989. A177. J. Epidemiol. 133, 296–304 (1991).
   Google Scholar
• Hoskins TVV, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1, 33–35 (1979).
   Google Scholar
• Davies JR. Grilli EA. Natural or vaccine- induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epiderniol. Infect. 102,325-333 (1989). (Erratum appears in Epidemiol. Infect. 103,217 [19891).
   Google Scholar
• European Medicines Evaluation Agency. Note for guidance on harmonization of requirements for influenza vaccines. European Medicines Evaluation Agency London, UK (1997).
   Google Scholar
• Potter CW Determinants of immunity to influenza infection in man. Br. Med. Bull. 335,69–75 (1979).
   Google Scholar
• National Institutes of Health. Specific immunity in influenza B summary of influenza workshop 111.1 Infect. Dis. 127, 220–236 (1973).
   Google Scholar
• Fox JP, Cooney MK, Hall CE, Hjordis ME Influenza virus infections in Seattle families, 1975–1979. Am. J Epiderniol. 116,228-242 (1982).
   Google Scholar
• Hjordis MF, Cooney MK, McMahan R, Bor E, Grayston JT. Single-dose monovalent A2/Hong Kong influenza vaccine efficacy 14 months after immunization. JAMA 217,1067–1071 (1971).
   Google Scholar
• Hoskins TVV, Davies JR, Smith AJ et al. Influenza at Christ's Hospital: March 1974. Lancet1,105–108 (1976).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. Carr. Topics Microbiol. II77177111701. 146,107-116 (1989).
   Google Scholar
• Gorse GJ, Belshe RB. Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin. Microbiol. 28,2539–2550 (1990).
   PubMed Web of Science ®Google Scholar
• Halloran ME, Longini IM Jr, Gaglani MJ et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am. J Epiderniol. 158, 305–311 (2003).
   Google Scholar
• Lee MS, Mahmood K, Adhikary L et al. Measuring antibody responses to a live-attenuated influenza vaccine in children. Pediatr. Infect. Dis. J (2004). In press.
   Google Scholar
• Mendelman PM, Rappaport R, Cho I et al. Live-attenuated influenza vaccine induces crossreactive antibody responses in children against an A/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J 23,1–3 (2004).
   Google Scholar
• Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 899–906 (2000).
   Google Scholar
• King JC, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect. Dis. 177,1394–1397 (1998).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R. Cold-adapted, trivalent, influenza vaccine study group. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr. Infect. Dis. 22,28–34 (2003).
   Google Scholar
• Gorse GJ, O'Connor TZ, Newman FK et al. Immunity to influenza in older adults with chronic obstructive pulmonary disease. Infect. Dis. 190,11–19 (2004).
   Google Scholar
• Gruber WC, Belshe RB, King JC et al. Evaluation of live attenuated influenza vaccines in children 6–18 months of age: safety, immunogenicity, and efficacy. J Infect. Dis. 173,1313-1319 (1996).
   Google Scholar
• Nolan T, Lee MS, Cordova JM et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 21, 1224–1231 (2003).
   PubMed Web of Science ®Google Scholar
• Bridges CB, Thompson WW Meltzer MI et al. Effectiveness and cost benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 284, 1655–1663 (2000).
   PubMed Web of Science ®Google Scholar
• Edwards KM, DuPont WD, Westrich MK et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect. Dis. 169,68–76 (1994).
   PubMed Web of Science ®Google Scholar
• Clover RD, Crawford S, Glezen WP et aL Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect. Dis. 163, 300–304 (1991).
   Google Scholar
• Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284,1655–1663 (2000).
   PubMed Web of Science ®Google Scholar
• Tam JS, Capeding MR, Lum LCS et al. Efficacy of a live attenuated influenza vaccine (CAIV-T) in children living in Southeast Asia against community-acquired culture-confirmed influenza. Options for the Control of Influenza V. Okinawa, Japan, Abstract WO3P-05 (2003).
   Google Scholar
• Vesikari T, Aristegui JF, Ashkenazi S and et al. Efficacy of a live attenuated influenza vaccine in children aged 6 to 36 months attending day care centers in Europe and Israel against community-acquired culture-confirmed influenza. Options for the control of influenza V Okinawa, Japan, Abstract W07-5 (2003).
   Google Scholar
• Ashkenazi S, Vertruyen A, Aristegui J et al. Comparison of safety and efficacy of a trivalent live attenuated, intranasal influenza vaccine (CAIV-T) with trivalent inactivated intramuscular influenza vaccine (TIV) in children aged 6 to 72 months with a history of respiratory tract infections. Pediatric Academic Societies' Annual Meeting. San Francisco, CA, USA, Abstract LB7 (2004).
   Google Scholar
• Fleming D, Crovari P, Wahn U et al. Comparison of safety and efficacy of a trivalent live attenuated, intranasal influenza vaccine (CAIV-T) with trivalent inactivated intramuscular influenza vaccine (TIV) in children and adolescents aged 6 to 8 years with asthma. Pediatric Academic Societies' Annual Meeting, CA, USA, Abstract LB20 (2004).
   Google Scholar
• Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23, 138–144 (2004).
   PubMed Web of Science ®Google Scholar
• Redding G, Walker RE, Hessel C et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr. Infect. Dis. 21,44–48 (2002).
   Google Scholar
• Jackson LA, Holmes SI Mendelman PM et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17,1905–1909 (1999).
   Google Scholar
• Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Int. Med. 117, 625–633 (1992).
   PubMed Web of Science ®Google Scholar
• Gorse GJ, O'Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 21, 2133–2144 (2003).
   PubMed Web of Science ®Google Scholar
• King JC Jr, Treanor J, Fast PE et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect. Dis. 181,725–728 (2000).
   Google Scholar
• King JC Jr, Fast PE, Zangwill KM et al., the HIV Influenza Study Group. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr. Infect. Dis. 10,1124–1131 (2001).
   Google Scholar
• Cha T-A, Kao K, Zhao J et al. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J. Clin. MicrobioL 38,839–845 (2000).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Van Voris LP. Cold- recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J Infect. Dis. 149,735-740 (1984).
   Google Scholar
• Clements ML, Snyder MH, Sears SD et al. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J Infect. Dis. 161,869-877 (1990).
   Google Scholar
• Couch RB, Quarles JM, Cate TR et al. Clinical trials with live cold-reassortant influenza virus vaccines. In: Options for the Control of Influenza. Kendal AP, Patriarca PA (Eds). Alan R Liss, Inc., NY, USA, 223–241 (1986).
   Google Scholar
• Davenport FM, Hennessy AV, Minuse E et al. Pilot studies on mono- and bivalent live attenuated influenza virus vaccines. Proceedings of the Symposium on Live Influenza Vaccine 105–113 (1971).
   Google Scholar
• Davenport FM, Hennessy AV, Maassab HF et al. Pilot studies on recombinant cold-adapted live Type A and B influenza virus vaccines. J Infect. Dis. 136,17–25 (1977).
   PubMedGoogle Scholar
• Moritz AJ, Kunz C, Hofman H et al. Studies with a cold-recombinant ANictoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers. J Infect. Dis. 142,857-860 (1980).
   Google Scholar
• Reeve P, Gerendas B, Moritz A et al. Studies in man with cold-recombinant influenza virus (H1N1) live vaccines. J. Med. ViroL 6, 75–83 (1980).
   Google Scholar
• Van Voorthuizen F, Jens D, Saes F. Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains. Antiviral Res. 1,107-122 (1981).
   Google Scholar
• Wright PF, Okabe N, McKee KT Jr et al. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect. Dis. 146,71–79 (1982).
   Google Scholar
• Wright PF, Johnson PR, Karzon DT Clinical experience with live, attenuated vaccines in children. In: Options for the Control of Influenza. Kendal AP, Patriarca PA (Eds). Alan R Liss, Inc., NY, USA, 243–253 (1986).
   Google Scholar
• Vesikari T, Karvonen A, Korhonen T et al. A randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of alive, attenuated, cold-adapted influenza virus vaccine (CAIV-T) in children attending day care. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), IL, USA, Abstract G-450 (2001).
   Google Scholar